Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, has secured a major client for the new Rentschler Biopharma Manufacturing Center (RBMC) facility at its manufacturing site in Milford, Massachusetts.
The RBMC is planned to be operational in the second half of 2024.
The company, a long-standing client of Rentschler Biopharma in Germany, has contracted to have its product lead manufactured at the RBMC for clinical supply.
This innovative protein therapeutic is seeking to address a form of cancer. Rentschler Biopharma successfully produced cGMP-quality product for early phase clinical testing at its manufacturing site in Laupheim, Germany. The project will now be transferred to the US for additional supply.
Federico Pollano, Senior Vice President Business Development of Rentschler Biopharma, said: “We are delighted to have our client place their trust in us to manufacture their product for their continued clinical development."
"An important aspect of our services is the seamlessness of our operations across sites and our consistent delivery of top-quality products. We strive to be a true partner with our clients and look forward to bringing more projects, from both new and existing clients to our new state-of-the-art US facility.”
Benedikt von Braunmühl, CEO of Rentschler Biopharma, commented: “Rentschler Biopharma is committed to reducing the complexity of biopharmaceutical manufacturing for our clients, and our RBMC facility was designed to be easily adaptable to meet clients’ evolving needs as they advance and grow."
"This announcement highlights the strategic significance of our US operations in growing our international capabilities and reinforces our dedication to being a provider of comprehensive development and production solutions for the biopharmaceutical industry. Moreover, it underlines our commitment to advancing medicine to save lives, together with our clients and partners.”